/Investor DB

DEFTA Partners — Full Portfolio

23 tracked investments · listed companies and verified rows first

Actuate Therapeuticsactuatetherapeutics.comin𝕏NASDAQ: ACTUMay 2019 · $21.7M

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a small-molecule GSK-3β inhibitor designed to treat difficult-to-treat cancers including pancreatic, melanoma, lung, and pediatric cancers through intravenous injection and oral tablet formulations.

BiotechFort Worth, US

Daniel Schmitt(President & Chief Executive Officer)Paul Lytle(Executive Officer)inAndrew Mazar(Executive Officer)

BoardTodd Thomson(Director)inRoger Sawhney(Director)Jason Keyes(Director)

Co-investorsBios PartnersIllinois VenturesKairos Venture Investments, LlcNuFund Venture GroupBiosTech Coast Angels

Abilitech Medicalabilitechmedical.com

HealthtechSt. Paul, US

Angeline Conley(Executive Officer, Director)Aaron Fletcher(Director)inDonald Santel(Director)Steve Seme(Executive Officer)

Co-investorsIrishAngelsSoutheast Minnesota Capital Fund

Actuateactuate.aiin𝕏May 2019 · $21.7M

Actuate provides AI-based video analytics that turn existing IP cameras and NVRs into a security detection system, offering real-time alerts for threats such as intruders, loitering, guns, and crowds.

AI & Machine LearningCloud ComputingCybersecurityGovTechSaaS

Sonny Tai(Co-Founder)inKen Francis(CEO)in

Co-investorsBios PartnersBling CapitalDorm RoomGray Line PartnersMetaPropMetaProp Ventures+4 more

Aegle Therapeuticsaegletherapeutics.comDec 2025

Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells.

BiotechHealthtechMedical DevicesWoburn, US

Shelley A. Hartman(Co-founder & CEO)inEvangelos V. Badiavas(Founder & Chief Scientific Officer)Heidi Kempinski(Chief Operational Officer)inKathleen Murphy(Head of Clinical Operations)Robert Williamson, Jr.(Executive Officer, Director)Robert Ryan(Director)

Co-investorsDeepWork CapitalNew World AngelsOcean Azul Partners

anamneanamne.com

Anamne operates "おうち病院" (Ouchi Byoin), an online medical consultation service that connects patients with doctors via video call for diagnosis, prescriptions, and health management from home.

Digital HealthHealthtech

Bacchusb2i.co.jp

Integrated foundry business offering contract services and products for microbial production of useful substances.

Co-investorsKobe University Capital

Cambrian Biocambrianbio.comin𝕏

Cambrian Bio is a clinical-stage drug development company creating precision therapeutics that target metabolic pathways which decline with age, such as AMPK and mTOR.

BiotechHealthtechLongevityNew York, US

James Peyer(CEO, Founder, Board Director)inMark Nuttall(Chief Business Officer)inRuth Thieroff-Ekerdt(Chief Medical Officer)inBill DeVaul(Chief Legal Officer)in

BoardChristian Angermayer(Chairman, Co-Founder, Board Director)inMaryanna Saenko(Director)in

Co-investorsAlumni VenturesCatalio Capital Management, LPFJ LabsFuture VenturesKhosla VenturesKorify Capital+5 more

CMEDcmed.com.bd

CMED Health delivers preventive and primary care in Bangladesh by combining AI tools, IoT point-of-care devices, and community health workers to provide screening, risk assessment, telemedicine consultations, GP clinics, and hospital referrals.

AI & Machine LearningDigital HealthIoTDhaka, BD

DiA Imaging Analysisdia-analysis.comAug 2021Acquired

AI-based ultrasound analysis technology using machine learning to deliver fast and accurate clinical indications.

Co-investorsAgate Medical Investments LPICON - Israel Collaboration NetworkMindset VentureConnecticut InnovationsIsrael Innovation AuthorityOutlier Ventures+3 more

Endogenaendogena.comSeries A · Jan 2021 · $8M

Endogena Therapeutics develops endogenous regenerative medicines aimed at treating degenerative diseases, with a program focused on retinal conditions such as those causing blindness.

BiotechMedical DevicesZürich, CH

Immusoftimmusoft.comJan 2019 · $20M

Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.

BiotechDeep TechHealthtechSeattle, US

Matthew Scholz(Founder)inSean Ainsworth(Chief Executive Officer)inRobert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)inScott McIvor(Chief Development Officer)Eric Garcia(Executive Officer)in

Co-investorsBioRock VenturesBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital Network+6 more

InformAIinformai.comin𝕏Seed · Jun 2020 · $1.8M

InformAI develops AI-guided clinical solutions for oncology and diagnostic imaging to improve patient treatment outcomes.

AI & Machine LearningDigital HealthHealthtechMedical DevicesHouston, US

Co-investorsJoyance PartnersSocial StartsJP Morgan Chase

ONTERA INC.twoporeguys.com

Two Pore Guys is a diagnostics company developing a handheld nanopore-based analyte sensor for point-of-care testing, with applications including liquid biopsy cancer detection.

BiotechDeep TechDigital HealthHardwareMedical DevicesSanta Cruz, US

Co-investorsKhosla Ventures

PhotoQ3photoq3.com

PhotoQ3 is a research and development company developing gentle treatment methods for diseases that currently lack cures.

BiotechHealthtechMedical Devices

Qoloqolo.jp

Qolo is a University of Tsukuba spin-off that develops and sells rehabilitation and mobility devices enabling users to stand and move, including a standing-up training device and a mobility model with a stand-up function.

HardwareMedical DevicesMobility & TransportationTsukuba, JP

QuantuMDxquantumdx.comin𝕏

QuantuMDx develops point-of-care molecular diagnostics platforms and assays for detecting infectious diseases including sexually transmitted infections, antimicrobial resistance, respiratory viruses, and other pathogens.

Digital HealthHealthtechMedical DevicesNewcastle upon Tyne, GB

Elaine Warburton(Co-Founder and former CEO)

Co-investors3B Future Health FundAdjuvo

savonixsavonix.comSeries A · Apr 2019 · $10M

Co-investorsRethink Impact

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Alio, Inc.Arris PharmaceuticalsBioEclipse TherapeuticsbracNetIsis PharmaceuticalsViagene

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.